[go: up one dir, main page]

MX2012006265A - Formulaciones disacaridas hipersulfatadas. - Google Patents

Formulaciones disacaridas hipersulfatadas.

Info

Publication number
MX2012006265A
MX2012006265A MX2012006265A MX2012006265A MX2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A
Authority
MX
Mexico
Prior art keywords
hypersulfated
compounds
agents
disaccharides
delivery
Prior art date
Application number
MX2012006265A
Other languages
English (en)
Inventor
Tahir Ahmed
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of MX2012006265A publication Critical patent/MX2012006265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)

Abstract

Se describen los disacáridos hipersulfatado con utilidad en asma o padecimientos relacionados con as asma. Los compuestos se formulan con agentes que mejoran el suministro oral de los disacáridos hipersulfatados. Los agentes liberadores se seleccionan del grupo que consiste de polímeros naturales o sintéticos que tienen cadenas laterales iónicas como otros compuestos o tipos de compuestos que mejoran la disponibilidad de los disacáridos relacionados con el suministro del medicamento sin dichos agentes. Los disacáridos hipersulfatados se realizan de heparina o sales de los mismos.
MX2012006265A 2009-12-03 2010-11-23 Formulaciones disacaridas hipersulfatadas. MX2012006265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26636109P 2009-12-03 2009-12-03
PCT/US2010/057787 WO2011068721A1 (en) 2009-12-03 2010-11-23 Hypersulfated disaccharide formulations

Publications (1)

Publication Number Publication Date
MX2012006265A true MX2012006265A (es) 2012-07-25

Family

ID=44082618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006265A MX2012006265A (es) 2009-12-03 2010-11-23 Formulaciones disacaridas hipersulfatadas.

Country Status (10)

Country Link
US (3) US8546351B2 (es)
EP (1) EP2506711B1 (es)
JP (2) JP5860811B2 (es)
KR (1) KR101763440B1 (es)
CN (1) CN102711463B (es)
CA (1) CA2781923C (es)
MX (1) MX2012006265A (es)
RU (1) RU2576033C2 (es)
TW (1) TWI481408B (es)
WO (1) WO2011068721A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506711B1 (en) * 2009-12-03 2019-04-03 OPKO Health, Inc. Hypersulfated disaccharide formulations
WO2012058424A1 (en) * 2010-10-29 2012-05-03 Opko Health, Inc. Hypersulfated disaccharides to treat elastase related disorders
JP5871500B2 (ja) * 2011-06-20 2016-03-01 公益財団法人先端医療振興財団 α−Ｋｌｏｔｈｏ／ＦＧＦ２３複合体形成阻害化合物
CN106338423B (zh) 2015-07-10 2020-07-14 三斯坎公司 组织学染色的空间复用
US20190002596A1 (en) * 2015-12-30 2019-01-03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Sulfated heparin oligosaccharide and preparation method and application thereof
WO2018035050A1 (en) 2016-08-16 2018-02-22 Opko Pharmaceuticals, Llc Pure heptasulfated disaccharides having improved oral bioavailability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
ES2058129T3 (es) * 1986-12-23 1994-11-01 Fisons Plc Composiciones farmaceuticas que comprenden una solucion acuosa de un derivado de piranoquinolina.
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US5990096A (en) 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5498410A (en) 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5639469A (en) 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
CZ20021443A3 (cs) * 1999-10-29 2003-01-15 Smithkline Beecham Corporation Způsob podávání inhibitoru fosfodiesterázy 4
US6635702B1 (en) 2000-04-11 2003-10-21 Noveon Ip Holdings Corp. Stable aqueous surfactant compositions
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
EP1379235B1 (en) 2000-10-10 2006-12-20 University Of North Carolina At Chapel Hill Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
DK1381620T3 (da) * 2001-04-16 2006-06-26 Ivax Research Inc Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US20030180348A1 (en) 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005075490A2 (en) * 2004-02-03 2005-08-18 Ivax Corporation Synthesis of polysulfated uronic acid glycosides
US20080249165A1 (en) 2004-08-05 2008-10-09 Ivax Drug Research Institute Ltd. Glycosides and Salts Thereof
ATE397006T1 (de) 2004-08-05 2008-06-15 Ivax Drug Res Inst Ltd Polysulfatierte glykoside und salze davon
WO2006017752A2 (en) 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CA2652205A1 (en) 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
EP2506711B1 (en) * 2009-12-03 2019-04-03 OPKO Health, Inc. Hypersulfated disaccharide formulations

Also Published As

Publication number Publication date
US20110136757A1 (en) 2011-06-09
JP2016028039A (ja) 2016-02-25
US8546351B2 (en) 2013-10-01
US9006211B2 (en) 2015-04-14
JP6158259B2 (ja) 2017-07-05
US20130345167A1 (en) 2013-12-26
CA2781923C (en) 2018-08-14
CN102711463B (zh) 2015-05-13
EP2506711A1 (en) 2012-10-10
WO2011068721A1 (en) 2011-06-09
KR101763440B1 (ko) 2017-08-14
RU2012120833A (ru) 2014-01-10
CA2781923A1 (en) 2011-06-09
CN102711463A (zh) 2012-10-03
US20160250242A1 (en) 2016-09-01
EP2506711B1 (en) 2019-04-03
JP2013512904A (ja) 2013-04-18
EP2506711A4 (en) 2013-04-10
RU2576033C2 (ru) 2016-02-27
JP5860811B2 (ja) 2016-02-16
KR20120104583A (ko) 2012-09-21
TW201124142A (en) 2011-07-16
TWI481408B (zh) 2015-04-21

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
IL219865A0 (en) Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof
MX2013001677A (es) Formulaciones estables de linaclotida.
IN2012DN02736A (es)
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MX2013004491A (es) Boronatos como inhibidores de arginasa.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MA33939B1 (fr) 5-alcynyl-pyrimidines
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2013000733A (es) Composiciones de noribogaina.
MY173521A (en) Trpv4 antagonists
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
WO2012048129A3 (en) Inhibitors of polo-like kinase
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201300990A1 (ru) Парентеральное введение тапентадола
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.

Legal Events

Date Code Title Description
FG Grant or registration